News Agencies Feed

healthcare

Dec 06

Hasbani: MoPH against introducing pesticides containing carcinogens

Hasbani: MoPH against introducing pesticides containing carcinogens

NNA - Deputy Prime Minister and caretaker Minister of Public Health, Ghassan Hasbani, said via Twitter: 'The Ministry of Public Health still adhere to its position against the introduction of agricultural pesticides containing carcinogens, despite the decision acquired by the Ministry"...

Continue Reading >>

Dec 06

CosmeSurge Recruit ‘Ladies of London’ Caroline Stanbury as Their New Brand Ambassador

CosmeSurge Recruit ‘Ladies of London’ Caroline Stanbury as Their New Brand Ambassador

CosmeSurge has appointed self-made Londoner Caroline Stanbury, as their ambassador. CosmeSurge, who support charitable causes noted the philanthropic efforts of the media tycoon, who will be co-hosting BOVET 1822’s charitable gala in Dubai this month. The natural competitive drive"...

Continue Reading >>

Dec 06

Takeda Shareholders Approve Resolutions Related to the Proposed Acquisition of Shire plc

Takeda Shareholders Approve Resolutions Related to the Proposed Acquisition of Shire plc

(AETOS Wire)-- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

Takeda"...

Continue Reading >>

Dec 06

Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas

Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas

(AETOS Wire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) announced that data from the ECHELON-2 phase 3 clinical trial will be presented today in an oral session at the 60th American Society of Hematology (ASH) Annual Meeting. The data demonstrated that frontline treatment with ADCETRIS (brentuximab vedotin) in combination with CHP (cyclophosphamide, doxorubicin, prednisone) is effective in extending progression-free survival (PFS) and overall survival (OS) with a safety profile comparable to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), a current standard of care in patients......

Continue Reading >>

Dec 05

High Hopes Pediatric Therapy Center Celebrates First Anniversary and Reinforces Its Commitment to the Super Special Ones in the Middle East

High Hopes Pediatric Therapy Center Celebrates First Anniversary and Reinforces Its Commitment to the Super Special Ones in the Middle East

High Hopes Pediatric Therapy Center, Dubai’s fully integrated facility for children with moderate to complex special needs, celebrated its first anniversary by reinforcing its commitment to families of children with special needs.

In"...

Continue Reading >>

Dec 05

Takeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3 Placebo Controlled Trial Evaluating Proteasome Inhibitor Treatment in Maintenance Setting

Takeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3 Placebo Controlled Trial Evaluating Proteasome Inhibitor Treatment in Maintenance Setting

(AETOS Wire)-- Takeda Pharmaceutical Company Limited (TSE:4502) today announced that data from the Phase 3 randomized, TOURMALINE-MM3 study evaluating the effect of single-agent oral NINLARO™ (ixazomib) as a maintenance therapy in adult patients"...

Continue Reading >>

Dec 05

Takeda Announces Execution of Loan Agreement in Connection with Proposed Acquisition of Shire plc

Takeda Announces Execution of Loan Agreement in Connection with Proposed Acquisition of Shire plc

(AETOS Wire) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

Takeda"...

Continue Reading >>

Dec 05

ResMed to Acquire Propeller Health, a Leader in COPD and Asthma Connected Health Solutions, for $225 Million

ResMed to Acquire Propeller Health, a Leader in COPD and Asthma Connected Health Solutions, for $225 Million

(AETOS Wire) -- ResMed (NYSE: RMD) (ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital software-as-a-service (SaaS) business solutions, today announced it has entered a definitive agreement to acquire Propeller Health, a digital"...

Continue Reading >>

Dec 04

Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018

Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018

(AETOS Wire)-- Celgene Corporation (NASDAQ: CELG) today announced initial data from the dose-escalation part of an ongoing, open-label multicenter phase 1/2 study of investigational lisocabtagene maraleucel (liso-cel; JCAR017) in patients with relapsed/refractory"...

Continue Reading >>

Dec 04

Tiziana Completes Patient Enrollment in a Phase 2a Trial to Evaluate Tolerability and Anti-Tumor Activity of Milciclib in Hepatocellular Carcinoma (HCC)

Tiziana Completes Patient Enrollment in a Phase 2a Trial to Evaluate Tolerability and Anti-Tumor Activity of Milciclib in Hepatocellular Carcinoma (HCC)

(AETOS Wire) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that patient enrollment in the"...

Continue Reading >>